Pharmaceutical giant Eli Lilly has reinforced its dominance in the rapidly growing obesity treatment market after presenting promising trial results for its experimental drug retatrutide. Data shared at the American Diabetes Association conference showed the once-weekly injection could deliver greater weight loss than any obesity drug currently available or under